REPLY TO QUERY FROM BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") DATED 12 APRIL 2021

We refer to your Company’s announcement dated 9 April 2021, in respect of the aforesaid matter.
In this connection, kindly furnish Bursa Securities with the following additional information for public release:-

1) The duration of the MOU and the date of commencement thereof.
2) Whether the MOU is subject to a definitive agreement to be entered into by UCrest Berhad (“UCrest”) and RDIF.
3) To quantify the Vaccines to be purchased by RDIF from UCrest.
4) To state how UCrest will derive revenue from the contract manufacturing / selling of the Vaccines to RDIF.
5) The total capital and investment outlay required to be committed by UCrest in connection with the Venture, the source(s) of funding and the breakdown thereof.

6) The relevant regulatory approvals, permits and/or licenses required to be obtained in order for UCrest to perform its responsibilities under the MOU. To also state whether UCrest has secured any of these regulatory approvals, permits and/or licences, and the relevant dates of application and approval
7) UCrest’s future plans and prospects in connection with the collaboration with RDIF on the Vaccines.
8) To elaborate on the financial risk and production risk associated with the MOU.

Please furnish Bursa Securities with your reply within one (1) market day from the date hereof.

Yours faithfully,
Listing, 
Regulation

Cc : Market Surveillance Dept. , Securities Commission (via fax)